Belatacept: Uses for Kidney Transplant and Side Effects

Belatacept is an immunosuppressive drug given by intravenous infusion to prevent rejection in adults who have received a kidney transplant. It works differently from the standard pills most transplant recipients take: instead of broadly suppressing immune-cell signaling inside the cell, belatacept blocks a specific interaction on the surface of T cells that is needed for those cells to activate against the transplanted organ. In large clinical trials, it has been linked to better long-term kidney function and a lower risk of death or graft loss compared with cyclosporine, one of the older mainstay drugs. But it also carries a distinct set of risks, including higher early rejection rates and specific infectious concerns, that shape who is a good candidate and how closely they need to be monitored.

How Belatacept Works

Your immune system recognizes a transplanted kidney as foreign and mounts an attack led largely by T cells. For a T cell to fully activate, it needs two signals. The first comes when the T cell’s receptor recognizes a foreign protein. The second, called costimulation, happens when a molecule called CD28 on the T cell binds to molecules called CD80 and CD86 on the surface of immune cells presenting that foreign protein. Without that second handshake, the T cell’s response is blunted. Belatacept is a fusion protein that latches onto CD80 and CD86 and blocks them from engaging CD28, effectively cutting the costimulation wire.

This mechanism sets belatacept apart from calcineurin inhibitors like cyclosporine and tacrolimus, which work inside the T cell to block a signaling enzyme. Calcineurin inhibitors are effective but are directly toxic to kidney tissue over time, a serious drawback when the whole point of the transplant is to restore kidney function. Belatacept avoids that particular toxicity, which is a large part of its appeal.

Long-Term Survival and Graft Outcomes

The strongest evidence for belatacept comes from the BENEFIT trial, a large randomized study comparing two belatacept dosing regimens against cyclosporine in recipients of standard-criteria donor kidneys. At one year, patient and graft survival rates were comparable across all three groups, with belatacept regimens at roughly 95–97% and cyclosporine at 93%.¹ The more striking numbers emerged over a longer follow-up. Both belatacept regimens showed about a 43% reduction in the risk of death or graft loss compared with cyclosporine, a benefit driven equally by fewer deaths and fewer graft losses.²

Five-year data from the same trial reinforced the pattern. No graft losses occurred in either belatacept group by five years, while about 2% of cyclosporine-treated patients lost their grafts. Deaths were also less common with belatacept: roughly 1–2% in each belatacept arm versus about 5% with cyclosporine.³ These long-term numbers suggest that belatacept’s kidney-sparing properties translate into a real survival advantage over years.

Kidney Function Over Time

If there is one area where belatacept consistently outperforms calcineurin inhibitors, it is kidney function itself. In the BENEFIT trial, the measured glomerular filtration rate (a standard gauge of how well the kidney filters blood) was about 13 mL/min higher in belatacept-treated patients than in cyclosporine-treated patients at one year.¹ Over time, that gap widened: kidney function gradually improved in the belatacept groups while declining in the cyclosporine group at a rate of about 1 mL/min per year, eventually producing roughly a 25 mL/min difference in favor of belatacept.⁴

This matters because chronic calcineurin-inhibitor toxicity is one of the leading contributors to gradual graft failure. A transplanted kidney that functions better and improves over time rather than slowly declining gives the recipient a longer window before needing dialysis again or another transplant.

Metabolic and Cardiovascular Benefits

Heart disease is the leading cause of death in kidney transplant recipients, so the metabolic profile of an immunosuppressive regimen carries real weight. In pooled data from the BENEFIT and BENEFIT-EXT trials, belatacept-treated patients had systolic blood pressure readings roughly 6 to 9 mmHg lower and diastolic readings 3 to 4 mmHg lower than those on cyclosporine at one year. Non-HDL cholesterol and triglycerides were also lower in the belatacept groups.⁵

New-onset diabetes after transplant is another concern with calcineurin inhibitors, particularly tacrolimus, which is directly toxic to the insulin-producing cells in the pancreas. A meta-analysis comparing belatacept with tacrolimus found that the incidence of new-onset diabetes at one year was substantially lower with belatacept.⁶ That said, one smaller randomized trial that converted patients from tacrolimus to belatacept found that patients who already had diabetes did not reverse it after switching, so the benefit may be more about prevention than cure.⁷

Higher Early Rejection Rates

The trade-off that has kept belatacept from fully replacing calcineurin inhibitors is rejection. In the BENEFIT trial’s long-term follow-up, acute rejection at 12 months was about 17–22% in the belatacept groups versus 7% with cyclosporine, and some of those rejections were more severe histologically.⁸ A separate multicenter trial testing belatacept with simultaneous steroid withdrawal confirmed the pattern: biopsy-proven acute cellular rejection was higher in both belatacept arms, though antibody-mediated rejection rates were similar across groups.⁹

Most of these rejection episodes happen in the first few months and respond to treatment, and they do not appear to erase the long-term survival advantage described above. Still, they mean that belatacept patients need vigilant monitoring in the early post-transplant period, with protocol biopsies and close lab follow-up to catch rejection before it does lasting damage. In one large single-center analysis of 341 patients converted to belatacept, 51 episodes of acute cellular rejection were recorded, underscoring that the risk persists and requires ongoing surveillance.¹⁰

Infection Risks

Because belatacept suppresses a specific arm of the immune system, its infection profile differs somewhat from calcineurin inhibitors. Two viral infections get the most attention: cytomegalovirus (CMV) and BK polyomavirus.

A systematic review and meta-analysis found no statistically significant difference in overall CMV infection risk between belatacept and calcineurin-inhibitor-treated patients.¹¹ However, when CMV does occur in belatacept patients, it can behave unusually. One case report documented persistent, erratic CMV viremia lasting over a year in a patient switched to belatacept, illustrating that the viral course can be prolonged and harder to predict.¹² A registry-based study also linked belatacept to higher rates of severe CMV viremia (high viral loads above 25,000 copies/mL) and clinical CMV disease, even though the overall incidence of any detectable viremia was similar between groups.¹³

BK virus is similarly nuanced. That same registry study found no difference in overall BK viremia or BK-associated kidney damage, but a higher rate of severe BK viremia in belatacept patients.¹³ The practical takeaway is that belatacept does not necessarily cause more viral infections overall, but when infections happen, they can be more intense and harder to clear, making regular viral-load monitoring essential.

Post-Transplant Lymphoproliferative Disorder and EBV Status

The most serious risk unique to belatacept is post-transplant lymphoproliferative disorder (PTLD), a type of cancer driven by unchecked growth of white blood cells, often triggered by Epstein-Barr virus (EBV). Early clinical trials found that patients who were EBV-seronegative before transplant, meaning they had never been exposed to EBV, were at notably higher risk for PTLD when given belatacept. Because of this, belatacept’s labeling contraindicates its use in EBV-seronegative recipients. An analysis of the national Organ Procurement and Transplantation Network database identified a case of PTLD in an EBV-seronegative patient who received belatacept at transplant; that patient died from PTLD within the first year.¹⁴

For this reason, every patient being considered for belatacept is tested for EBV antibodies. If the test shows no prior exposure, belatacept is off the table. This is particularly relevant for younger patients and some children, who are less likely to have encountered EBV.

A Rare but Serious Neurological Complication

Progressive multifocal leukoencephalopathy (PML) is a rare brain infection caused by the JC virus, which normally lies dormant in most people without causing problems. In a transplant recipient whose immune system is suppressed, however, the virus can reactivate and destroy the protective coating around nerve fibers in the brain. A case report described rapidly fatal PML in a kidney transplant patient treated with belatacept, where the patient’s T cells appeared unable to mount any response against JC virus even after the drug was stopped.¹⁵ PML is extremely rare, but its severity means it appears in belatacept’s prescribing information as a boxed warning alongside the PTLD risk.

Switching from a Calcineurin Inhibitor to Belatacept

Many patients are not started on belatacept at the time of transplant but are switched to it later, typically because their kidney function is declining on tacrolimus or cyclosporine, or because they are developing side effects from those drugs. Studies looking at this conversion strategy consistently show improvements in kidney function. In one study of patients with evidence of blood-vessel damage in their graft biopsies, eGFR rose from about 35 to nearly 44 mL/min over 12 months after switching to belatacept.¹⁶ Another study found that late conversion also improved acid-base balance, bone metabolism, and protein metabolism beyond what the kidney-function gains alone would explain.¹⁷

A broader review of conversion data found that early switches (within the first six months) produced larger eGFR gains but also a higher risk of opportunistic infections, while later switches yielded more modest but sustained improvements with fewer infectious complications.¹⁸ A phase II randomized trial specifically testing the feasibility of switching found that acute rejection did occur in some converted patients, but all episodes resolved without graft loss, and overall safety was comparable between groups.¹⁹ The decision of when to convert involves weighing the urgency of stopping calcineurin-inhibitor toxicity against the infection and rejection risks of early switching.

Extended-Criteria and Higher-Risk Donor Kidneys

One area where belatacept’s kidney-protective profile is especially appealing is in transplants from marginal donors, kidneys that come from older donors or have other characteristics that make them more vulnerable to drug toxicity. The BENEFIT-EXT trial studied this population over seven years. While survival rates were similar between belatacept and cyclosporine groups (the hazard ratio hovered near 1.0 and was not statistically significant), kidney function told a different story: eGFR in the belatacept groups climbed gradually over seven years, reaching about 54 mL/min, while eGFR in the cyclosporine group declined steadily to about 35 mL/min.²⁰

A single-center study using a belatacept-first protocol for high-risk donor kidneys (those with prolonged cold storage times, donation after cardiac death, or high Kidney Donor Profile Index scores) reported one-year patient survival of about 97% and graft survival near 95%, with mean eGFR around 55 mL/min.²¹ These kidneys are frequently discarded because they are considered too fragile for calcineurin-inhibitor-based regimens, so a belatacept-first approach could expand the pool of usable organs.

Donor-Specific Antibodies and Sensitized Patients

One lingering concern with any immunosuppressive regimen is whether the patient develops new antibodies against the donor kidney. A study comparing belatacept and tacrolimus found that new donor-specific antibodies appeared at similar rates in both groups, with about 9% of belatacept patients and 13% of tacrolimus patients developing them.²² A separate randomized phase 3b trial found that conversion to belatacept actually led to lower rates of new donor-specific antibodies (1% versus 7% in those continuing calcineurin inhibitors), though biopsy-proven rejection was slightly higher in the belatacept arm.²³

For highly sensitized patients, those who already carry a broad panel of antibodies against many potential donors, belatacept has shown an intriguing ability to reduce preexisting HLA class I antibodies. One study found a significant decrease in the breadth and strength of these antibodies in belatacept-treated patients compared with controls.²⁴ A small early-phase trial is now testing belatacept combined with daratumumab as a desensitization strategy for patients who are so highly sensitized that finding a compatible kidney is extremely difficult, with initial results showing depletion of antibody-producing cells in both blood and bone marrow.²⁵

Steroid-Free Regimens

Long-term steroid use after transplant contributes to weight gain, bone loss, diabetes, and other problems, so there is strong motivation to drop steroids when possible. A large single-center analysis of over 500 patients converted to belatacept compared outcomes between those who continued steroids and those who stopped. Rejection rates were similar in both groups (about 6%), and graft loss rates did not differ significantly.²⁶ An earlier exploratory trial also demonstrated that belatacept-based regimens could enable simultaneous avoidance of both calcineurin inhibitors and steroids, with more than two-thirds of patients remaining free of both at one year and kidney function about 8–10 mL/min higher than with tacrolimus.²⁷

The Infusion Experience and Patient Satisfaction

Unlike oral calcineurin inhibitors taken daily at home, belatacept is given as an intravenous infusion. During the first three months after transplant, infusions are typically given every two weeks; after that, they move to a once-monthly schedule. Each infusion takes about 30 minutes plus time for travel and check-in, which is a real commitment. Despite that, patient-satisfaction studies paint a surprisingly positive picture. One survey found that recipients were generally satisfied with belatacept therapy and felt the potential benefits justified drawbacks like travel time and limited control over scheduling.²⁸ A separate cross-sectional study reported high satisfaction scores across multiple dimensions, including side effects (scoring about 94 out of 100), general opinion of the therapy (also about 94), and convenience (around 82).²⁹

Some patients actually prefer the infusion model because it builds in a regular touchpoint with their transplant team, and it removes the anxiety of remembering to take daily pills at exactly the right time. Missed or late doses of tacrolimus can cause drug-level swings that increase rejection risk, whereas belatacept’s monthly schedule offers a longer and more forgiving window.

Vaccine Response

Because belatacept blocks T-cell costimulation, it can interfere with the immune system’s ability to respond to vaccines. This became especially visible during the COVID-19 pandemic. A study examining the immune response to mRNA COVID-19 vaccines in kidney transplant recipients found that those on belatacept had a significantly lower antibody response compared with patients on tacrolimus. The researchers noted that timing the vaccine dose at least 21 days after a belatacept infusion, maximizing the interval between drug exposure and vaccination, appeared to improve the response.³⁰ This is relevant not just for COVID-19 but for flu shots, pneumonia vaccines, and any other immunizations your transplant team recommends. If you are on belatacept, it is worth discussing the timing of vaccinations relative to your infusion schedule.

Pregnancy and Reproductive Safety

Evidence on belatacept use during pregnancy is thin. Animal studies exist, but human data are limited to small case series. A review of pregnancy outcomes after belatacept exposure in solid organ transplant recipients described the evidence as scarce, with no large cohort studies to draw from.³¹ A case series specifically examining kidney transplant recipients who were exposed to belatacept during pregnancy acknowledged that knowledge on its safety during pregnancy and breastfeeding remains limited to animal data.³² For women of childbearing age on belatacept, the practical implication is that contraception planning and pre-pregnancy counseling with a transplant specialist are essential, since the safety profile simply is not established enough to guide confident decision-making.